Cite

    Rebordosa, C. et al. (2022). Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists. Pharmacoepidemiology and drug safety. 31 (8), pp. 827-839. [Online].